Enhancer Reprogramming Confers Dependence on Glycolysis and IGF signaling in KMT2D Mutant Melanoma
Authors:
- Mayinuer MaitituohetiMMMayinuer Maitituoheti
- Emily Z. KeungEKEmily Z. Keung
- Ming TangMTMing Tang
- Liang YanLYLiang Yan
- Hunain AlamHAHunain Alam
- Guangchun HanGuangchun Han
- Ayush T. RamanARAyush T. Raman
- Christopher TerranovaCTChristopher Terranova
- Sharmistha SarkarSSSharmistha Sarkar
- Elias OroujiEOElias Orouji
- Samir B. AminSASamir B. Amin
- Sneha SharmaSSSneha Sharma
Preprint
Abstract
SUMMARY: Epigenetic modifiers have emerged as important regulators of tumor progression. We identified histone methyltransferase KMT2D as a potent tumor-suppressor through an in vivo epigenome-focused pooled RNAi screen in melanoma. KMT2D harbors frequent somatic point mutations in multiple tumor types. How these events contribute to tumorigenesis and whether they impart therapeutic vulnerability are poorly understood. To address these questions, we generated a genetically engineered mouse model of melanoma based on conditional and melanocyte-specific deletion of KMT2D. We demonstrate KMT2D as a bona fide tumor suppressor which cooperates with activated BRAF. KMT2D-deficient tumors showed substantial reprogramming of key metabolic pathways including glycolysis. Glycolysis enzymes, intermediate metabolites and glucose consumption rate were aberrantly upregulated in KMT2D mutant cells. The pharmacological inhibition of glycolysis reduced proliferation and tumorigenesis preferentially in KMT2D mutant cells. Mechanistically, KMT2D loss caused drastic reduction of H3K4me1-marked active enhancer states. Loss of distal enhancer and subsequent reduction in expression of IGFBP5 activated IGF1R-AKT to increase glycolysis in KMT2D-deficient cells. We conclude that KMT2D loss promotes tumorigenesis by facilitating increased usage of glycolysis pathway for enhanced biomass needs via enhancer reprogramming. Our data imply that inhibition of glycolysis or IGFR pathway could be a potential therapeutic strategy in KMT2D mutant tumors.Keywords
All Related Versions
- Published version: Cell Reports, 33 (3), 108293.
This publication has 74 references indexed in Scilit:
- MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor GenesMolecular Cell, 2018
- KMT2D regulates p63 target enhancers to coordinate epithelial homeostasisGenes & Development, 2018
- Cancer statistics, 2018CA: A Cancer Journal for Clinicians, 2018
- Targeted agents and immunotherapies: optimizing outcomes in melanomaNature Reviews Clinical Oncology, 2017
- The cancer epigenome: Concepts, challenges, and therapeutic opportunitiesScience, 2017
- The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma developmentNature Medicine, 2015
- Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesisNature Medicine, 2015
- Emerging patterns of somatic mutations in cancerNature Reviews Genetics, 2013
- Interplay between the Cancer Genome and EpigenomeCell, 2013
- A Landscape of Driver Mutations in MelanomaCell, 2012